Neumora Therapeutics NMRA
NASDAQ NMRA
$1.32 -0.03 (-2.60%)
As of: Sep 4, 2026 · 12:48 PM EDT

Neumora Therapeutics (NMRA) Non Operating Interest Expenses (2025 - 2026)

Analysis

Neumora Therapeutics (NMRA) Non Operating Interest Expenses (2025 - 2026) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 139.76 Bn 131.91 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.72 Bn 77.72 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.56 Bn 58.38 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.87 Bn 52.73 Bn 52.00 Mn -
5 Revolution Medicines 44.06 Bn 44.06 Bn - 23.78 Mn
6 BeOne Medicines 40.08 Bn 34.98 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.50 Bn 32.20 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.54 Bn 27.70 Bn - 93.62 Mn
9 Insmed 27.49 Bn 26.33 Bn 358.27 Mn 20.27 Mn
10 Neumora Therapeutics 243.49 Mn 243.49 Mn - 1.82 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.82 Mn
Mar 31, 2026 1.85 Mn
Dec 31, 2025 2.04 Mn
Sep 30, 2025 747,000.00
Jun 30, 2025 436,000.00